Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech BRISBANE, CA, March 31, 2021 — Delpor, Inc. (Delpor), a clinical stage [...]
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may receive additional funding in order [...]
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, June 14, 2017 –Delpor, Inc. [...]
The patent covers Delpor’s PROZORTM technology which enables the sustained release of antipsychotics and other molecules from a matchstick-size implant device. Delpor has several products in development, including a 6-month formulation of risperidone, and a 3-month [...]
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees. Delpor expects to meet with several potential partners interested [...]
The NIMH funds Delpor’s efforts to utilize its PROZORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering olanzapine for 3 months through passive diffusion. The product is expected to improve medication adherence during [...]
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin. SAN FRANCISCO, CA, April 23, 2015 – Delpor, Inc. (Delpor), [...]
The NIDDK funds Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, Oct 14, 2014 – Delpor, Inc. (Delpor), [...]
Delpor’s innovative Prozor technology receives support from the National Institute of Mental Health in an effort to reduce relapse in patients suffering from schizophrenia and bipolar disorder. SAN FRANCISCO, CA, June 20, 2012 –Delpor, Inc. [...]
Delpor continues to strengthen its expertise in drug delivery with the addition of the former CEO of Glaxo and Alza to its Board of Directors. SAN FRANCISCO, CA, January 19, 2012 – Delpor, Inc. (Delpor), [...]